Building on this unexpected finding, we asked whether IL-2cx could be used to potentiate cancer immunotherapy in the context of ICI treatment, and whether CD25-biased or CD25-blocking IL-2cx would lead to superior antitumor activity when combined with ICIs. Here, IL2RA is linked to cancer.